PMID: 8963037Sep 1, 1995Paper

Comparison of lansoprazole and omeprazole in the short-term management of duodenal ulcers in Taiwan

Journal of Gastroenterology and Hepatology
F Y ChangS D Lee

Abstract

Lansoprazole is a novel H+/K+-ATPase inhibitor which exhibits a very potent and long-acting suppression of acid secretion. The object of this randomized, controlled trial was to compare duodenal ulcer healing rates after 4 weeks of treatment with a once-daily regimen of either 30 mg lansoprazole or 20 mg omeprazole. Of a total of 111 patients 57 received lansoprazole, whereas 54 received omeprazole. In intention-to-treat analysis at 4 weeks, 89.5% patients showed ulcer healing following treatment with lansoprazole compared with 83.3% of patients treated with omeprazole. Per protocol analysis indicated that 96.1% of patients treated with lansoprazole showed ulcer healing, compared with 93.6% of patients treated with omeprazole (NS). Age, smoking or ulcer size did not affect the ulcer healing rate. Both agents could effectively and quickly resolve ulcer symptoms. The Helicobacter pylori clearance was seen in 36 (73.5%) patients in the lansoprazole group and in 40 (80%) patients in the omeprazole group after four weeks of treatment (NS). In addition, both agents led to hypergastrinaemia, by approximately 1.6 fold. Adverse side effects included a few occurrences of reversible skin rash and constipation. It is concluded that lansopr...Continue Reading

References

Jan 1, 1992·Scandinavian Journal of Gastroenterology. Supplement·I N MarksG O Young
Jan 1, 1992·Scandinavian Journal of Gastroenterology. Supplement·A Garner
Jan 1, 1992·European Journal of Clinical Pharmacology·I BerlinJ Duchier
Jan 1, 1992·Scandinavian Journal of Gastroenterology·K E McCollJ Harwood
Jun 1, 1992·Digestive Diseases and Sciences·M HongoT Toyota
Jun 15, 1991·Lancet·F MegraudH Lamouliatte
Mar 1, 1991·Journal of Gastroenterology and Hepatology·K H LaiS D Lee
Dec 13, 1990·The New England Journal of Medicine·M Feldman, M E Burton
Dec 20, 1990·The New England Journal of Medicine·M Feldman, M E Burton
Apr 4, 1991·The New England Journal of Medicine·P N Maton
Apr 1, 1991·Digestive Diseases and Sciences·S Holt, C W Howden
Apr 1, 1989·Alimentary Pharmacology & Therapeutics·P MüllerB Simon
Feb 1, 1989·Gastroenterology·D Y Graham
Jan 1, 1986·Scandinavian Journal of Gastroenterology. Supplement·B Wallmark
Jan 1, 1986·Scandinavian Journal of Gastroenterology. Supplement·B Dickson
Jul 2, 1983·British Medical Journal·R P WaltR E Pounder
Jul 21, 1995·The Medical Letter on Drugs and Therapeutics
Feb 1, 1993·Digestive Diseases and Sciences·D C MetzR T Jensen
Jan 1, 1993·Alimentary Pharmacology & Therapeutics·K D Bardhan
Jan 1, 1993·Alimentary Pharmacology & Therapeutics·M Mignon, T Vallot
Jan 1, 1993·Alimentary Pharmacology & Therapeutics·J W Freston

❮ Previous
Next ❯

Citations

Aug 10, 2000·Alimentary Pharmacology & Therapeutics·C A Stedman, M L Barclay
Jun 26, 2001·Journal of Intellectual Disability Research : JIDR·C J BöhmerS G Meuwissen
May 21, 2003·Alimentary Pharmacology & Therapeutics·R M KlokJ R B J Brouwers
Oct 11, 2003·Journal of Gastroenterology and Hepatology·Full-Young ChangShou-Dong Lee
Apr 1, 1997·Journal of Clinical Periodontology·M A SalonenK S Oikarinen
Feb 18, 2011·The Cochrane Database of Systematic Reviews·Paul MoayyediClare Donnellan
Jun 26, 2001·Journal of Clinical Periodontology·D van SteenbergheR Jacobs
Mar 17, 2001·Clinical Oral Implants Research·A G PayneJ F Lownie

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.